Loading
Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML.
Andrew Wei was principal investigator of VIALE-C (venetoclax plus low-dose cytarabine) and first author of QUAZAR AML-001, which showed oral azacitidine maintenance improves survival after remission in older AML patients, the first maintenance therapy approved in AML. He leads the Australasian Leukaemia and Lymphoma Group AML programme and the venetoclax-based intensive chemotherapy trials.
Shares Peter MacCallum Cancer Centre, BCL-2, Venetoclax, MRD / molecular residual disease testing and the tags venetoclax, australia.
Shares BCL-2, Venetoclax, Acute myeloid leukaemia and the tags aml, venetoclax.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing and the tag venetoclax.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing and the tag venetoclax.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing.
Shares BCL-2, Venetoclax and the tag australia.
Shares BCL-2, Venetoclax, Acute myeloid leukaemia.